Anti-annexins autoantibodies: Their role as biomarkers of autoimmune diseases

Autoimmunity Reviews

Volumn 10, Issue 9, 2011, Pages 553-558

  Iaccarino, L ^a   Ghirardello, A ^a   Canova, M ^a   Zen, M ^a   Bettio, S ^a   Nalotto, L ^a   Punzi, L ^a   Doria, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Annexins; Anti annexin antibodies; Pregnancy loss; Systemic rheumatic disease; Thrombosis

Indexed keywords

ANNEXIN; ANTIINFLAMMATORY AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; LIPOCORTIN 1; LIPOCORTIN 2; LIPOCORTIN 5;

ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; CALCIUM SIGNALING; CELL DIVISION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONNECTIVE TISSUE DISEASE; CYTOLOGY; DISCOID LUPUS ERYTHEMATOSUS; HUMAN; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

ANNEXINS; ANTIBODIES; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; FEMALE; HUMANS; PREGNANCY;

EID: 79957883066     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.007     Document Type: Review

References (52)

1. Hayes M.J., Moss S.E. Annexins and disease. Bioch Biophysic Res Comm 2004, 322:1166-1170.
2. Fatimathas L., Moss S.E. Annexins as disease modifiers. Histol Histopathol 2010, 25:527-532.
3. Hughes G.R. Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics. Lupus 2010, 19:343-346.
4. Rojas-Villarraga A., Toro C.E., Espinosa G., Rodríguez-Velosa Y., Duarte-Rey C., Mantilla R.D., et al. Factors influencing polyautoimmunity in systemic lupus erythematosus. Autoimmun Rev 2010, 9:229-232.
5. Khamashta M.A. Hughes syndrome: 'sticky blood'. Clin Exp Rheumatol 2009, 27:1-2.
6. Peretti M., D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009, 9:62-70.
7. Lim L.H., Solito E., Russo-Marie F., Flower R.J., Perretti M. Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: effect of lipocortin 1. Proc Natl Acad Sci U S A 1998, 95:14535-14539.
8. Zen M., Canova M., Campana C., Bettio S., Nalotto L., Rampudda M., et al. The kaleidoscope of glucocorticoid effects on immune system. Autoimmun Rev 2011, 10:305-310.
9. Goulding N.J., Podgorski M.R., Hall N.D., Flower R.J., Browning J.L., Pepinsky R.B., et al. Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1989, 48:843-850.
10. Kretz C.C., Norpo M., Abele-Dorner L., Linke B., Haust M., Edler L., et al. Anti-annexin 1 antibodies. A new diagnostic marker in the serum of patients with discoid lupus erythematosus. Exp Dermatol 2010, 19:919-921.
11. Bano S., Bombardieri S., Doria A., Iaccarino L., Lehmann P., Mosca M. Lupus erythematosus and the skin. Clin Exp Rheumatol 2006, 24(1 Suppl. 40):S26-S35.
12. Hajjar K.A., Jacovina A.T., Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. J Biol Chem 1994, 269:21191-21197.
13. Ling Q., Jacovina A.T., Deora A., Febbraio M., Simantov R., Silverstein R.L., et al. Annexin II is a key regulator of fibrin homeostasis and neoangiogenesis. J Clin Invest 2004, 113:38-48.
14. Ishii H., Yoshida M., Hiraoka M., Hajjar K.A., Tanaka A., Yasukochi Y., et al. Recombinant annexin II modulates impaired fibrinolytic activity in vitro in rat carotid artery. Circ Res 2001, 89:1240-1245.
15. Olwill S.A., McGlynn H., Gilmore W.S., Alexander H.D. Annexin II cell surface and mRNA expression in human acute myeloid leukemia cell lines. Thromb Res 2005, 115:109-114.
16. Zhang J., McCrae K.R. Annexin II mediates endothelial cell activation by antiphospholipid/anti-beta2glycoprotein I antibodies. Blood 2005, 105:1964-1969.
17. Matsuura E., Shen L., Matsunami Y., Quan N., Makarova M., Geske F.J., et al. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus 2010, 19:379-384.
18. Cesarman-Maus G., Rios-Luna N.P., Deora A.B., Huang B., Villa R., Cravioto Mdel C., et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107:4375-4382.
19. Cesarman-Maus G., Cantù-Brito C., Barinagarrementeria F., Villa R., Reyes E., Sanchez-Guerrero J., et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke 2011, 42:501-503.
20. Salle V., Mazière J.C., Smail R., Cévallos R., Mazière C., Fuentes V., et al. Anti-annexin II antibodies in systemic autoimmune disease and antiphospholipid syndrome. J Clin Immunol 2008, 28:291-297.
21. Frank M., Sodim-Semrl S., Irman S., Bozic B., Rozman B. Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. Autoimmun Rev 2009, 9:5-10.
22. van Genderen H.O., Kenis H., Hofstra L., Narula J., Reutelingsperger C.P.M. Extracellular annexin A5: functions of phosphatidilserine-binding and two-dimensional crystallization. Biochim Biophys Acta 2008, 1783:953-963.
23. Reutelingsperger C.P.M., Van Heerde W.L. Annexin V the regulator of phosphatidilserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Sci 1997, 53:527-532.
24. Wang X., Campos B., Kaezel M.A., Dedman J.R. Annexin V is critical in the maintenance of murine placental integrity. Am J Obstet Gynecol 1999, 180:1008-1016.
25. Matsuda J., Gotoh M., Saitoh N., Gohch K., Tsukmoto M., Yamamoto T. Anti-annexin V antibodies sera of patients with habitual foetal loss or preeclampsia. Thromb Res 1994, 75:105-106.
26. Gris J.C., Quéré I., Sanmarco M., Buotiere B., Mercier E., Amiral J., et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent early foetal loss. Thromb Haemost 2000, 84:228-236.
27. Matsubayashi H., Arai T., Izumi S., Sugi T., McIntyre J.A., Tsunehisha Makino Anti-annexin V antibodies in patients with early pregnancy loss of implantation failure. Fertil Steril 2001, 76:694-699.
28. Gris J.C., Perneger T.V., Quéré I., Mercier E., Fabbro-Peray P., Lavigne-Lissalde G., et al. Antiphospholipid/antiprotein antibodies, haemostasis related autoantibodies, and plasma homocystein as risk factor for first pregnancy loss: a matched case control study. Blood 2003, 102:3504-3513.
29. Zammiti W., Mtiraoui N., Hidar S., Fekih M., Almawi W.Y., Mahjoub T. Antibodies to β2-glycoprotein I and annexin V in women with early and late idiopathic recurrent spontaneous abortions. Arch Gynecol Obstet 2006, 274:261-265.
30. Bizzaro N., Tonutti E., Villalta D., Tampoia M., Tozzoli R. Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005, 129:61-68.
31. Bizzaro N., Antico A., Musso M., Platzgummer S., Camogliano L., Tozzoli R., et al. A prospective study of 1038 pregnancies on the predictive value of anti-annexin V antibodies for foetal loss. Ann NY Acad Sci 2005, 1050:348-356.
32. Alijotas-Reig J., Ferrer-Oliveras R., Rodrigo-Anoro M.J., Farrn-Codina I., Llura-Olivé E., Vilardell-Tarres M., et al. Anti-annexin A5 antibodies in women with spontaneous pregnancy loss. Med Clin (Barc) 2010, 134:433-438.
33. Arnold J., Holmes Z., Pickering W., Farmer C., Regan L., Cohen H. Anti-beta2 glicoprotein I and of anti-annexin V antibodies in women with recurrent miscarriages. Br J Haematol 2001, 113:911-914.
34. Rand J.H., Wu X.X., Quinn A.S., Taatjes D.J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010, 19:460-469.
35. Kaburaki J., Kuwana M., Yamamoto M., Kawai S., Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997, 54:209-213.
36. Satoh A., Suzuki K., Takayma E., Kojima K., Hidaka T., Kawakami M., et al. Detection of anti-annexin V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999, 26:1715-1720.
37. Cederholm A., Svenungsson E., Jensen-Urstad K., Trollmo C., Ulfgren A.K., Swedenborg J., et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005, 25:198-203.
38. Nojima J., Kuratsune H., Suehisa E., Futsukaichi Y., Yamanishi H., Machii T., et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patient with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001, 47:1008-1015.
39. Asherson R.A., Francès C., Iaccarino L., Khamashta M.A., Malacarne F., Piette J.C., et al. The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol 2006, 24(1 Suppl. 40):S46-S51.
40. Matsuura E., Kobayashi K., Matsunami Y., Lopez L.R. The immunology of atherothrombosis in the antiphospholipid syndrome: antigen presentation and lipid intracellular accumulation. Autoimmun Rev 2009, 8:500-505.
41. Bizzaro N., Ghirardello A., Zampieri S., Iaccarino L., Tozzoli R., Ruffatti A., et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007, 5:1158-1164.
42. Sugiura K., Muro Y. Anti-annexin V antibodies and digital ischemia in patient with scleroderma. J Rheumatol 1999, 26:2168-2172.
43. Habeeb R.A., Mansour H.E., Abdeldayem A.M., Abo-shady R.A., Hassan I.A., Saafan N.K., et al. Anti-annexin V antibodies: association with vascular involvement and disease outcome in patients with systemic sclerosis. Clin Med Insights Arthritis Musculoskelet Disord 2010, 3:15-23.
44. Leclerc E., Fritz G., Weibel M., Heizman C.W., Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation and products) immunoglobulin domains. J Biol Chem 2007, 282:31317-31331.
45. Hofman S., Franke A., Fischer A., Jacobs G., Nothnagel M., Gaede K.I., et al. Genome-wide association study identifies ANX11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008, 40:1103-1106.
46. Ghirardello A., Bendo R., Rampudda M.E., Bassi N., Zampieri S., Doria A. Commercial blot assays in the diagnosis of systemic rheumatic diseases. Autoimmun Rev 2009, 8:645-649.
47. van Venrooij W.J., Wodzing K.W., Habes W.J., de Rooij D.J., van de Putte L.B. Anti-56KD a novel, frequently occurring autoantibody specificity in connective tissue diseases. Clin Exp Rheumatol 1989, 7:277-282.
48. Misaki Y., van Venrooij W.J., Pruijn G.J.M. Prevalence and characteristics of anti-56K/annexin XI autoantibodies in systemic autoimmune diseases. J Rheumatol 1995, 22:97-102.
49. Jørgensen S., Levantino G., Houen G., Jacombsen S., Halberg P., Ullman S., et al. Determination of autoantibodies to annexin in systemic autoimmune diseases. Lupus 2000, 9:515-520.
50. Doria A., Zen M., Canova M., Bettio S., Bassi N., Nalotto L., et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010, 10:55-60.
51. Sarzi-Puttini P., Atzeni F., Gerli R., Bartoloni E., Doria A., Barskova T., et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 2010, 9:849-852.
52. Zampieri S., Adami N., Biral D., Ghirardello A., Rampudda M.E., Vecchiato M., et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010, 9:449-453.